Zydus Lifesciences Q2 profit jumps 38% as US and China approvals sharpen global expansion strategy

Zydus Lifesciences Limited, listed on the National Stock Exchange under the ticker ZYDUSLIFE and on the BSE as 532321, reported a strong set of financials for the quarter ended September 30, 2025. Net profit for the quarter surged 38.1 percent year-on-year to ₹12,586 million. Consolidated revenues from operations rose 16.9 percent to ₹61,232 million, while EBITDA grew by a similar 38 percent to ₹20,158 million. EBITDA margins stood at 32.9 percent, an improvement of 500 basis points over the previous year, signaling strong operational leverage and disciplined cost management across business segments.

This performance came despite a marginal sequential decline from Q1 FY26 levels, which had been boosted by a broader base. The decline in quarter-on-quarter revenue of 6.9 percent was partly expected and attributed to product seasonality, delayed launches, and inventory rationalisation in select geographies. Nonetheless, the half-year picture remains consistent. Zydus Lifesciences Limited posted a 16.9 percent growth in net profit to ₹27,254 million for the first half of the fiscal year, with revenues reaching ₹126,969 million.

The company’s performance was bolstered by sustained contributions from its India formulations, United States formulations, international markets, consumer wellness, and medtech businesses. R&D investments came in at ₹4,820 million for the quarter, accounting for 7.9 percent of revenues, highlighting its continued emphasis on innovation and differentiated filings.

What segments contributed most to Zydus Lifesciences Limited’s Q2 FY26 performance across regions and therapies?

The United States formulations segment remained the single largest contributor, accounting for 45 percent of consolidated revenue. The business recorded ₹27,437 million in revenue, growing 13.5 percent year-on-year despite a sequential dip of 13.8 percent. In constant currency terms, this was equivalent to USD 313 million. During the quarter, Zydus Lifesciences Limited launched seven new products, filed six Abbreviated New Drug Applications, and received four approvals including one tentative nod.

India formulations revenue stood at ₹15,931 million, up 8.4 percent year-on-year, with chronic therapies like oncology, cardiology, and gynecology continuing to outperform the Indian Pharmaceutical Market. The business retained its leadership position in oncology and launched VaxiFlu, India’s first trivalent influenza vaccine.

The consumer wellness segment delivered ₹6,374 million in revenue, marking a 31 percent year-on-year rise. This was driven by the acquisition of United Kingdom-based Comfort Click Limited. The deal added three direct-to-consumer brands, WeightWorld, Maxmedix, and Animigo, into the company’s international wellness portfolio. Comfort Click’s revenue model is focused on e-commerce and digital-first channels in the United Kingdom, the European Union, and the United States.

International markets formulations revenue rose sharply by 39.4 percent year-on-year to ₹7,513 million, supported by strong growth across both developed and emerging markets. Zydus Lifesciences Limited maintained its momentum in Europe and reported healthy demand across therapeutic lines.

The medtech business contributed ₹1,532 million to the top line. This included the full consolidation of Amplitude Surgical following the acquisition of the remaining 14.4 percent stake in October 2025. Meanwhile, the Active Pharmaceutical Ingredients segment posted ₹1,472 million in revenue, up 23.3 percent over the previous year.

What approvals did Zydus Lifesciences Limited receive after Q2 and how do they strengthen its global regulatory footprint?

Shortly after reporting its Q2 FY26 results on November 6, Zydus Lifesciences Limited announced two significant regulatory milestones. On November 7, the company received tentative approval from the United States Food and Drug Administration for Olaparib Tablets in 100 mg and 150 mg strengths. The drug is a generic version of AstraZeneca’s Lynparza, a blockbuster treatment for BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. IQVIA data indicated that Olaparib tablets had recorded annual United States sales of USD 1.38 billion as of September 2025. The product will be manufactured at the company’s Special Economic Zone facility.

On November 11, Zydus Lifesciences Limited received its first drug approval in China. The National Medical Products Administration granted marketing authorisation for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg. The antidepressant is used in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. Production will take place at the group’s Moraiya site in Ahmedabad. This milestone marks Zydus Lifesciences Limited’s formal entry into China’s regulated generics market, a strategically important step given the relatively low presence of Indian drugmakers in the country.

These two post-earnings approvals, though not reflected in the Q2 financials, have been well-received by institutional trackers and are expected to bolster third quarter sentiment and sales visibility.

What is the current investor sentiment and how is Zydus Lifesciences Limited positioned for FY26?

Investor sentiment toward Zydus Lifesciences Limited remains positive, buoyed by the company’s focus on operational consistency, strategic acquisitions, and regulatory wins across high-growth markets. The stock has maintained relative stability around the ₹660 to ₹690 range on the National Stock Exchange and is frequently mentioned among mid-cap pharma gainers in institutional coverage.

Zydus Lifesciences Limited’s balance sheet remains strong with a net debt to equity ratio of just 0.09 times and net debt to EBITDA of 0.3 times as of September 30, 2025. Capex for the quarter stood at ₹4,911 million. The company also received clean regulatory reports during the period. Two manufacturing facilities, SEZ I Ahmedabad and Baddi, received Establishment Inspection Reports with Voluntary Action Indicated status, while the SEZ II Ahmedabad site secured a No Action Indicated designation following a pre-approval inspection.

Looking ahead, the company is preparing to file a New Drug Application for Saroglitazar Magnesium with the United States Food and Drug Administration in the fourth quarter of FY26. The compound met its primary endpoint in the EPICS-III Phase 2b/3 study for Primary Biliary Cholangitis. Additionally, regulatory clearance has been obtained to commence Phase II clinical trials for a bivalent typhoid conjugate vaccine in India. Both assets underline Zydus Lifesciences Limited’s parallel focus on generics and differentiated pipeline growth.

What are institutional flows and retail indicators telling us about near-term price action?

Recent activity suggests that domestic institutional investors continue to maintain stable positions in Zydus Lifesciences Limited, while foreign interest appears to have strengthened following the China and United States regulatory approvals. Market trackers point to strong earnings visibility, well-diversified revenue streams, and consistent compliance outcomes as key drivers of confidence across both retail and institutional segments.

Analysts believe that investor interest could rise further if commercialisation of Olaparib in the United States gains traction or if Zydus Lifesciences Limited accelerates its regulatory pace in China. Valuation multiples remain aligned with mid-cap pharmaceutical peers, but the company’s differentiated product mix, innovation pipeline, and expanding international footprint may support a moderate valuation premium in the quarters ahead.

Key takeaways from Zydus Lifesciences Limited’s Q2 FY26 performance and recent global approvals

• Zydus Lifesciences Limited posted a 38.1 percent rise in Q2 FY26 net profit to ₹12,586 million on revenue of ₹61,232 million

• EBITDA margin improved to 32.9 percent, reflecting robust operating efficiency

• United States and India formulations continued to drive top-line growth, complemented by international markets and consumer wellness

• The company received post-results approvals in the United States for Olaparib and in China for Venlafaxine ER Capsules

• These approvals mark significant regulatory milestones that strengthen the company’s footprint in large, regulated markets

• Saroglitazar Magnesium is on track for an NDA filing in Q4 FY26 following positive Phase 2b/3 trial data

• Investor sentiment remains constructive, with the stock showing steady performance and institutional confidence in innovation execution

• Balance sheet strength, global regulatory visibility, and a disciplined R&D strategy underpin a favorable long-term outlook